Director at Sutro Biopharma (STRO) receives 10,000 stock options as equity grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Sutro Biopharma director Connie Matsui received a new stock option grant covering 10,000 shares of Common Stock. The option has an exercise price of $26.09 per share and was granted as a compensation award, not an open-market purchase or sale. It vests in monthly installments of 8.33% starting on July 5, 2026. The award becomes fully vested and exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 5, 2027, assuming continued service.
Positive
- None.
Negative
- None.
Insights
Director received a routine stock option grant as equity compensation.
Connie Matsui, a director of Sutro Biopharma, was granted stock options for 10,000 shares of Common Stock at an exercise price of $26.09 per share. The Form 4 labels this as a grant or award acquisition, not a market transaction.
The options vest monthly at 8.33% starting on July 5, 2026, with full vesting by the earlier of the 2027 annual stockholders meeting or June 5, 2027, contingent on continued service. There are no sales, tax withholdings, or exercises reported, and derivativeSummary is empty, indicating only this new award is shown in this filing.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
MATSUI CONNIE
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 10,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 10,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 10,000 options
Exercise price: $26.09 per share
Total options after grant: 10,000 options
+3 more
6 metrics
Stock options granted
10,000 options
Grant covering 10,000 shares of Common Stock
Exercise price
$26.09 per share
Option exercise price for the 10,000-share award
Total options after grant
10,000 options
Derivative securities owned following the reported transaction
Vesting start date
July 5, 2026
First 8.33% monthly vesting tranche
Full vesting deadline
Earlier of 2027 meeting or June 5, 2027
Award fully vested and exercisable by that time
Expiration date
June 5, 2036
Option term end date
Key Terms
Stock Option (right to buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 26.0900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option shall vest, subject to the reporting person's provision of service"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-05T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What did Sutro Biopharma (STRO) report in this Form 4 for Connie Matsui?
Sutro Biopharma reported that director Connie Matsui received a grant of stock options covering 10,000 shares of Common Stock. The options are a compensation award and not an open-market trade, and they increase her potential future equity exposure.
How large is Connie Matsui’s new stock option grant at Sutro Biopharma (STRO)?
The grant covers 10,000 stock options, each for one share of Sutro Biopharma Common Stock. These options have an exercise price of $26.09 per share and represent additional potential ownership if she chooses to exercise them after vesting.
What are the vesting terms of Connie Matsui’s Sutro Biopharma stock options?
The options vest in monthly installments of 8.33%, beginning on July 5, 2026. They become fully vested and exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 5, 2027, assuming she continues serving the company.
What is the exercise price and expiration date of Connie Matsui’s STRO stock options?
The stock options have an exercise price of $26.09 per share and an expiration date of June 5, 2036. She can only exercise them once they have vested and before they expire, subject to the plan’s rules.
How many derivative securities does Connie Matsui hold after this transaction?
After the grant, the Form 4 shows 10,000 derivative securities (stock options) held following the transaction. This corresponds to options for 10,000 shares of Common Stock, reflecting the newly awarded grant reported in the filing.